Diane Haddock Russell

Ornithine Decarboxylase as a Biological and Pharmacological Tool

Ornithine decarboxylase, the initial enzyme in the polyamine biosynthetic pathway, is induced in target tissues in response to a variety of trophic agents including polypeptide and amine trophic hormones, cyclic AMP analogs, drugs, and trophic steroid hormones. The induction of ornithine decarboxylase in these systems is regulated at a transcriptional level and is proportional to the extent of stimulation. Because of its rapid half-life (10-20 min), a general maximum of induction is detectable within 4-5 h of stimulation, and its induction pattern can serve as a rapid, specific index of increased RNA and protein synthesis. Implications for its usefulness to pharmacologists, endocrinologists, physiologists, and biochemists are summarized.

Prolactin receptors on human lymphocytes and their modulation by cyclosporine

Prolactin receptors have been identified for the first time on human peripheral blood lymphocytes. These receptors are present on T- and B-cells as well as monocytes. The specific binding of [125I]prolactin to these cells can be selectively enhanced at certain concentrations and blocked by higher concentrations of cyclosporine , a known immunosuppressive agent which inhibits the mitogenesis of T-cells. Prolactin also induces ornithine decarboxylase, a key growth regulatory enzyme, in lymphocytes. Therefore, we suggest that the lymphocyte prolactin receptor may be involved in regulating lymphocyte function, and that one of the actions of cyclosporine is to block this rather ubiquitously occurring receptor.

Concanavalin A-stimulated murine splenocytes produce a factor with prolactin-like bioactivity and immunoreactivity.

Culture supernatants from concanavalin A activated murine splenic mononuclear cells (splenocytes) were assayed for prolactin-like molecules using the Nb2 node lymphoma bioassay and immunostaining procedures. Con A stimulated splenocytes produced a factor with prolactin-like immunoreactivity that was mitogenic for Nb2 lymphoma cells. This factor first appeared in culture supernatants with the onset of lymphocyte mitogenesis and its activity was proportional to the number of cells cultured. In addition, splenocyte proliferation was inhibited by antiserum to rat prolactin, and this inhibition was partially reversed by added hormone. These findings show that murine splenocytes produce a substance with prolactin-like activity and suggest that this factor is essential for lymphocyte proliferation.

Proposed model of major sequential biochemical events of a trophic response.

Abstract It appears that the induction of ornithine decarboxylase regulates the rate of ribosomal RNA synthesis as well as regulating the rate of synthesis of polyamines. Further, ornithine decarboxylase, in most cases, is induced after a significant activation of cAMP-dependent protein kinase. We propose a model for the process of hypertrophy based on studies of a considerable number of mammalian growth systems. The mechanism of parallel regulation of polyamines and RNA appears to be initiated by the direct effect of ornithine decarboxylase on RNA polymerase I.

Hypothyroxinemia and hypothermia in rats in response to 2,3,7,8-tetrachlorodibenzo-p-dioxin administration

The effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) treatment on body temperature and serum and tissue levels of thyroid hormones, glucose, glucagon, insulin, and somatostatin were investigated. Within 7 days following TCDD administration (45 micrograms/kg), rats exhibited hypothyroidism compared to pair-fed controls and rats fed ad libitum. Body temperature was maintained in the pair-fed and ad libitum-fed controls but was significantly decreased in TCDD-treated rats at 2 days. Within 2 weeks of the administration of 90 micrograms TCDD/kg, body temperature was below 35 degrees C with the lowest mean value of 34.5 degrees C recorded on Day 16. Mean body temperatures for control rats ranged from 36.8 to 37.5 degrees C. One week after TCDD administration (45 micrograms/kg), serum thyroxine (T4) declined to 46% of pair-fed controls. The decreased free-thyroxine index indicated that the measured decrease in thyroxine reflected decreased hormone concentrations as opposed to altered protein binding. Hypoglycemia occurred in TCDD-treated rats subsequent to hypothyroxinemia and hypothermia, but it did not develop in the pair-fed controls. At 1 week after administration of 45 micrograms TCDD/kg, serum and pancreatic insulin levels were reduced to 25 and 76% of ad libitum-fed controls, respectively. Hypophagia was determined to be responsible for the decreased growth rate and hypoinsulinemia but did not account for hypothyroxinemia, hypothermia, and hypoglycemia following the administration of TCDD. No significant alterations were detected in serum glucagon or in pancreatic, hepatic, or serum somatostatin levels. Decreased somatostatin in the gastric antrum coincided with a 29% increase in stomach dry weight. The delayed toxicity of TCDD may result, in part, from these hormonal alterations.

Type I and type II cyclic AMP-dependent protein kinase as opposite effectors of lymphocyte mitogenesis

THE role of cyclic AMP in the regulation of cell growth and differentiation has been extensively investigated in many cell types following various growth stimuli1,2. In recent years, peripheral blood lymphocytes treated with antigens3, plant lectins4, lipopolysaccharides5, or periodate oxidation6 have served as a model system for assessing whether cyclic AMP is involved in the regulation of the mitogenic response promoted in these cells by the above classes of agents7,8. There are two conflicting hypotheses, as outlined by Friedman1, concerning the role of cyclic AMP in lymphocyte proliferation. The first hypothesis suggests that the increase in cyclic AMP levels following mitogen stimulation8 and the subsequent increase in 32P incorporated into F1 histones9 and certain cystosol proteins10 implicates cyclic AMP as a positive mediator of mitogenesis in lymphocytes. The other hypothesis reasons that cyclic AMP inhibits proliferation, and this hypothesis is supported primarily by observations from several laboratories that raising the intracellular cyclic AMP level through the use of phosphodiesterase inhibitors11, prostaglandins12, or cyclic AMP analogues11,13–15 effectively inhibits mitogen-stimulated RNA and DNA synthesis. We present here evidence that may help resolve this apparent paradox. Incubation of Ficoll–Hypaque purified human peripheral blood lymphocytes with concanavalin A (conA) leads to the activation of only type I cyclic AMP-dependent protein kinase in these cells even though there are significant amounts of both type I and type II kinase present. But, the addition of dibutyryl cyclic AMP (DBcAMP) to the conA-stimulated lymphocytes at a concentration sufficient to block the synthesis of RNA and DNA results in the activation of both type I and type II cyclic AMP-dependent protein kinase. It therefore seems likely that while the activation of type I protein kinase represents a positive component in the progression of events promoted in a lymphocyte by a mitogenic signal (as it does in other cell types in which a trophic response is evoked), the activation of type II protein kinase (or perhaps types I and II in concert) represents a mechanism by which a negative influence can be imposed on the proliferative process by the generation of abnormally high levels of intracellular cyclic AMP.

Clinical Relevance of Polyamines

The polyamines, putrescine, spermidine, and spermine have been established as biochemical markers of normal and pathological growth. In malignancy, the urinary concentrations of spermidine reflect the tumor cell loss and the urinary level of putrescine is related both to the number of tumor cells in cell cycle and to the tumor cell loss factor. A greater than twofold increase in urinary spermidine within 72 hr of chemotherapy predicts a complete or a partial response with a high degree of accuracy. Urinary putrescine may be valuable, not only in assessing the early response to therapy but also in determining whether the chemotherapy promotes a later burst of cell proliferation. Erythrocyte spermidine concentrations also appear to track alterations in tumor kinetics. Alterations in intracellular and extracellular polyamines in other pathologies such as psoriasis, muscular dystrophy, and cystic fibrosis also accurately reflect the disease activity and, in those cases studied, response to therapy. Therefore, the determination of polyamine concentrations in extracellular fluids and in erythrocytes allows for (1) the early assessment of response to multimodality therapy, (2) disease or tumor staging, and (3) assessment of disease activity including long-term monitoring of polyamine concentrations to pinpoint remission and relapse in adjuvant patients. Information obtained by the monitoring of polyamines could result in prolongation of survival time of patients as well as assist in the design of the most effective therapy regimen for the pathology. Since other such specific kinetic markers are not available, polyamines should be clinically utilized to track tumor evolution and tumor response to therapy in those patients at high risk, in which such measurements could be translated into therapeutic efficacy.

Cyclic AMP, cyclic AMP-dependent protein kinase, and the regulation of gene expression.

Abstract Biological responses produced by cAMP in mammalian cells are remarkably diverse and differ profoundly from one cell type and tissue to another. However, it is thought at this time that all effects of cAMP are mediated through the activation of cAMP-dependent protein kinases. The specificity of the cellular response to cAMP has been considered to result from switching on a specific built-in program of action within the specialized cell type which has been developed during development and differentiation. This review deals with the questions of cAMP control of protein synthesis at the transcriptional and translational levels. Hypotheses are suggested in an attempt to explain the data in tissue preparations and whole animals which suggest that regulation of the synthesis of at least some proteins by cAMP-dependent protein kinases does occur at the transcriptional level.

The roles of the polyamines, putrescine, spermidine, and spermine in normal and malignant tissues

Abstract Despite the initial aversion to polyamine research which can be attributed to their peculiar nomenclature and to the erroneous idea that polyamines are products of bacterial decay, it appears that these ubiquitous amines play important roles in the physiological regulation of growth. Many of the definitive roles are yet to be elucidated, and these areas offer promise to biochemists. The evolution of the multifaceted ramifications of polyamines is not unlike that for cyclic AMP, which has profound effects at the cellular level. Further, we are at a stage at which basic knowledge of the roles of polyamines is becoming clinically relevant. We should begin to measure polyamines routinely to obtain clinical parameters which might allow for more efficacious treatment of cancer. No longer can the discussion of polyamines in biochemical textbooks be limited to a page and a half or no discussion at all, and no longer can well-informed scientists afford to neglect the importance and the far-reaching applications of polyamine research.

Cyclosporine inhibits prolactin induction of ornithine decarboxylase in rat tissues

Cyclosporine (CyA), formerly cyclosporin A, significantly inhibited the ability of prolactin (PRL) to elevate ornithine decarboxylase (ODC) activity in a variety of rat tissues. Administration of PRL to hypophysectomized rats also resulted in an induction of ODC activity which was inhibited markedly in all tissues studied in the presence of CyA. Transglutaminase ( TGase ) activity was not affected in any significant manner by PRL or CyA in most tissues studied. However, it was elevated in the adrenal by 10(-8) M PRL. Bromocryptine, which selectively antagonizes pituitary PRL release, decreased the kidney ODC basal levels to 30% of vehicle control and serum PRL level to 4.3 +/- 1.4 compared to 28 +/- 10 in controls, suggestive of PRL maintenance of steady-state ODC activity in the kidney. CyA administration did not affect the action of glucagon, a known cyclic AMP-mediated hormone, or 8-bromo-cyclic AMP on kidney ODC activity. The elevation of rat kidney ODC activity by dexamethasone and triiodothyronine (T3), compounds which elevated serum prolactin levels in all cases, was also blocked by administration of CyA. Epidermal growth factor (EGF), which did not induce rat kidney ODC activity by itself, was capable of producing a small increment in ODC activity in the presence of CyA. The marked effect of CyA to selectively block ODC induction by PRL may be due to the ability of CyA to interact with receptor-required phospholipids in membranes and thus to antagonize hormone-receptor interaction.